Amarin (AMRN) Stock Price, News & Analysis

Company Overview

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. The company’s primary product is VASCEPA, a prescription medicine containing icosapent ethyl, a highly purified form of eicosapentaenoic acid.

In the United States, VASCEPA was initially approved by the U.S. Food and Drug Administration in 2012 as an adjunct to diet for adults with very high triglyceride levels. In 2019, the FDA expanded its approval to include reducing the risk of cardiovascular events in certain adults with elevated triglycerides and established cardiovascular disease or diabetes with additional risk factors. The product is also marketed as VAZKEPA in certain international markets, including Europe, where it received regulatory approval for cardiovascular risk reduction.

Amarin was founded in 1993 and is incorporated in Ireland, with operations historically spanning the United States and international markets. The company has focused primarily on the development, regulatory approval and commercialization of icosapent ethyl and related cardiovascular applications, while adapting its commercial strategy in response to generic competition and changing market conditions.

Key Stats

• Today's Range: $13.58 to $13.90
• 50-Day Range: $13.55 to $14.70
• 52-Week Range: $12.96 to $20.90
• Volume: 50,664 shs
• Average Volume: 80,412 shs
• Market Capitalization: $287.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Sell

Amarin Stock Analysis - MarketRank™

Amarin scored higher than 19% of companies evaluated by MarketBeat, and ranked 823rd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Sell

Consensus Rating

Amarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 2 sell ratings.

Upside/Downside

The consensus price target for Amarin is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amarin has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Amarin are expected to grow in the coming year, from ($0.85) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amarin is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amarin is -13.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amarin has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.53% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 4.66.

Change versus previous month

Short interest in Amarin has recently decreased by 2.79%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amarin does not currently pay a dividend.

Dividend Growth

Amarin does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amarin insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.21% of the stock of Amarin is held by insiders.

Percentage Held by Institutions

22.25% of the stock of Amarin is held by institutions.

Company Calendar

• Last Earnings: 2/25/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AMRN
• CIK: 897448
• Web: www.amarincorp.com
• Phone: (531) 669-9020
• Fax: N/A
• Employees: 80
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Amarin: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: -4.6%
• Consensus Rating: Sell
• Rating Score (0-4): 1.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.80 million
• Net Margins: -14.56%
• Pretax Margin: -13.73%
• Return on Equity: -0.20%
• Return on Assets: -0.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.67
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $213.65 million
• Price / Sales: 1.35
• Cash Flow: $0.36 per share
• Price / Cash Flow: 37.76
• Book Value: $22.07 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 21,120,000
• Free Float: 20,234,000
• Market Cap: $287.87 million
• Optionable: Optionable
• Beta: 0.76